ClinicalTrials.gg
Not yet recruitingNCT07489053Updated Mar 25, 2026

Optimizing Functional Recovery After Breast Cancer Treatment

An interventional study of Individually tailored education and guided application to promote activity participation and Individually tailored guided application in Breast Neoplasms, sponsored by MGH Institute of Health Professions. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by MGH Institute of Health Professions · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to determine the best way to promote participation in vocational, social, physical, and instrumental activities of daily living in people who have completed treatment for early stage breast cancer.

The main question it aims to answer is: Which of the intervention components, alone or in combination, most effectively promote participation in vocational, social, physical, and instrumental activities of daily living?

Participants will be asked to try one of 8 combination of three intervention components that have been shown to promote activity participation: (1) priority elicitation, (2) education, and (3) guided application involving goal setting, problem-solving and action planning.

Read the detailed description

Breast cancer treatment creates physical, emotional, and practical challenges that disrupt routines and activities. After completion of curative treatment, one-third of cancer survivors report participation restrictions, defined as difficulties performing valued activities that reflect life roles. Participation restrictions can persist two to six years after breast cancer treatment, imposing personal and societal costs by hindering one's ability to fulfill career, civic, and caregiving roles. Addressing participation restrictions reflects the Cancer Moonshot Initiative call for research on ways to reduce the debilitating effects of cancer, yet there are no evidence-based interventions that are ready for large scale implementation.

Most survivorship research has targeted symptom management, yet that does not always translate into greater participation in role-relevant activities. Recent evidence demonstrates that participation can be enhanced even in the absence of symptom reduction. There are now a number of interventions that aim to increase participation through various combinations of self-management strategies like goal setting and problem-solving, priority elicitation, and education about activity adaptation, environmental modification, and energy management. While studies indicate that these strategies are feasible and appear to enhance participation, each study uses a different blend of strategies that are often not well-specified, creating uncertainty as to which strategies of the multi-component interventions are most potent and which may be unnecessary. This uncertainty reduces reproducibility and limits large-scale implementation.

The goal of this study is to identify mechanisms of action that reliably enhance participation in role-relevant activities after breast cancer treatment. The Multiphase Optimization STrategy (MOST) framework of intervention development uses engineering principles to build multi-component interventions that are both potent (i.e., produce clinically relevant outcomes) and parsimonious (i.e., contain no inactive ingredients). The first phase of MOST creates a conceptual model linking intervention components (i.e., strategies) and the intended targets and identifies an optimization criterion by which success will be judged. This study's optimization criterion is to find the combination of intervention components that has the largest effect on participation restrictions. This proposal reflects the second phase of MOST, the optimization phase, where the investigators will evaluate the degree to which each intervention component exerts an independent or synergistic effect on participation restrictions. The optimization phase ensures that the resulting intervention is composed only of components that are contributing to the outcome of interest.

This study will use a factorial experiment to test three intervention components that have been used with breast cancer survivors: (1) priority-elicitation and session tailoring; (2) cancer survivorship education; and (3) guided application involving goal setting, problem-solving, and action planning. The components each have a modest evidence base supporting their efficacy to reduce participation restrictions. However, they have different profiles regarding a) the time survivors need to invest and b) the skills practitioners need to successfully deliver. To move the science forward, it is crucial to develop a potent yet parsimonious intervention with empirically-supported mechanisms of action.

This study's research question is: Which components alone or in combination have the greatest impact on participation restrictions? Using the MOST framework, the investigators will conduct an optimization trial with a factorial design. The investigators will recruit 352 breast cancer survivors reporting participation restrictions in the first year following curative treatment; participants will be randomized to receive combinations of the 3 components.

Aim 1: To identify the intervention components that reduce participation restrictions (primary outcome). Intervention components: a) priority elicitation (priority-elicitation coaching versus following a static menu of goals and topics); b) cancer survivorship education (therapist-administered versus weblink); and c) guided application (included versus not). Criterion: A component will be considered effective if its presence produces a main or interaction effect of Cohen's d of > 0.30.

Aim 2: To test the conceptual model by determining the degree to which each intervention component affects the following proximal targets: H1: Priority elicitation will have the strongest effect on engagement in valued activities. H2: Cancer survivorship education will have the strongest effect on self-efficacy for managing health. H3: Guided application will have the strongest effect on adaptive coping.

Aim 3: To assemble an intervention package by evaluating the main effects and interactions with the following optimization criterion: The largest effect on participation restrictions.

02

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • randomized controlled trial
  • factorial experiment
  • rehabilitation
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 352 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

MGH Institute of Health Professions is the lead sponsor of 19 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18 years or older,
  2. Diagnosed with Stage 1-3 breast cancer and within one year of completion of locoregional treatment and/or therapy with curative intent and absence of disease recurrence,
  3. Experiencing reduced participation (i.e., a score of > 10 on the Work and Social Adjustment Scale).

Exclusion criteria

Exclusion Criteria:

  1. Non-English speaking.
  2. Non-correctable hearing loss.
  3. Moderate-severe cognitive impairment indicated by a score \< 3 on a 6-item cognitive screener.
  4. History of severe mental illness (i.e., schizophrenia, bipolar disorder), current major depressive disorder, active suicidal ideation, or active substance misuse documented within the medical record.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
352 participants (estimated)

Study arms

  • Experimental
    Priority elicitation, education, and guided application

    Weekly telephone or videoconference sessions with a coach where participants will discuss survivorship information and set goals and action plans that are tailored to personal priorities

    Behavioral: Individually tailored education and guided application to promote activity participation

  • Experimental
    Priority elicitation and guided application

    Weekly telephone or videoconference sessions with a coach where participants will set goals and action plans that are tailored to personal priorities; survivorship information tailored to personal priorities will be emailed to participants

    Behavioral: Individually tailored guided application

  • Experimental
    Priority elicitation and education

    Weekly telephone or videoconference sessions with a coach where participants will discuss survivorship information that is tailored to personal priorities

    Behavioral: Individually tailored education

  • Experimental
    Priority elicitation

    Telephone or videoconference sessions with a coach in the first and last week where participants will discuss personal priorities for recovery; survivorship information tailored to personal priorities will be emailed to participants each week

    Behavioral: Priority elicitation

  • Experimental
    Education and guided application

    Weekly telephone or videoconference sessions with a coach where participants will discuss survivorship information and set goals and action plans from a static menu of six different topics

    Behavioral: Static education and guided application

  • Experimental
    Guided application

    Weekly telephone or videoconference sessions with a coach where participants will set goals and action plans from a static menu of six different topics; survivorship information from a static menu of six different topics will be emailed to participants each week

    Behavioral: Static guided application

  • Experimental
    Education

    Weekly telephone or videoconference sessions with a coach where participants will discuss survivorship information from a static menu of six different topics

    Behavioral: Static education

  • Experimental
    Information

    Weekly survivorship education will be emailed to participants, from a static menu of six different topics

    Behavioral: Information

Interventions

  • BehavioralIndividually tailored education and guided application to promote activity participation

    This condition has high levels of the three components: (1) priority-elicitation and session tailoring; (2) cancer survivorship education; and (3) guided application involving goal setting, problem-solving, and action planning.

  • BehavioralIndividually tailored guided application

    This condition contains high levels of priority elicitation and guided application.

  • BehavioralIndividually tailored education

    This condition contains how levels of the components of priority elicitation and education

  • BehavioralPriority elicitation

    This condition contains the high level of the priority elicitation component

  • BehavioralStatic education and guided application

    This condition has high levels of the education and guided application components

  • BehavioralStatic guided application

    This condition contains high level of the guided application component

  • BehavioralStatic education

    This condition contains the high level of the education component

  • BehavioralInformation

    This condition contains the low levels of the three components

06

What researchers measure

Primary outcomes

  1. Participation satisfaction: PROMIS Satisfaction with Social Roles and Activities Short Form 8a

    Scores range from 8 to 40, with higher values representing greater satisfaction with ability to participate in social roles and activities.

    Time frame: Baseline to week 20

Secondary outcomes

  1. Participation ability: Ability to Participate in Social Roles and Activities Short Form 8a

    Scores range from 8 to 40, with lower values representing greater difficulty participating in social roles and activities

    Time frame: Baseline to 20 weeks

  2. Valuing Questionnaire: Engagement in valued activities

    Two subscales of five items each. Progress subscale ranges from 0 to 30 with high scores reflecting better concordance between values and actions. Obstruction subscale ranges from 0 to 30 with high scores reflecting more interference between values and actions.

    Time frame: Baseline to 20 weeks

  3. Self-efficacy for health management: Self-Efficacy for Managing Chronic Disease Scale

    Scores range from 6 to 60 with higher scores indicating higher self-efficacy

    Time frame: Baseline to 20 weeks

  4. Adaptive coping: Brief COPE subscales

    Three subscales of the Brief COPE: planning, active coping, and positive reframing. Scores on each subscale are calculated as the sum of two items, thus possible scores range from 0 to 6, with higher values representing greater use of active coping strategies.

    Time frame: Baseline to 20 weeks

Other outcomes

  1. Acceptability of intervention components

    Open-ended questions regarding acceptability and utility of components received

    Time frame: 8 weeks post-baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — This study is expected to generate qualitative and quantitative data from up to 352 people who have finished treatment for Stage 1-3 breast cancer within the past year). Qualitative data include answers to open-ended questions about the acceptability and utility of the intervention components. Qualitative data also include the treatment session documentation (e.g., topics of goals set, education delivered). Quantitative data include participant characteristics (e.g., age, gender, type of treatment, marital status) and answers to the survey outcome assessments of participation restrictions, adaptive coping, meaningful activity engagement, and self-efficacy. All raw and scored quantitative data will be de-identified, preserved, and made publicly available for at least 7 years post-publication of findings. The qualitative data (which is harder to de-identify and may contain sensitive information that the disclosure of which could negatively affect participants) will not be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The cleaned, final dataset will be entered into the Harvard Dataverse prior to the publication of the main outcomes. The dataset will be maintained there for at least seven years after the final publication from the study.for at least seven years post-publication of findings.

Access criteria: There will be no restrictions regarding the access of the quantitative data. The de-identified quantitative dataset will be made freely available, without requiring a request for permission.

Data sharing details ↗ · dataverse.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Sep 2030, 44 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 44 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Sep 30, 2030
CompletionEst.
Sep 30, 2030
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07489053
Lead sponsor
MGH Institute of Health Professions
Responsible party
Kathleen Lyons, ScD, OTR/L (Professor, MGH Institute of Health Professions) — Principal investigator
First posted
Mar 23, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Mar 25, 2026

Study contacts

Kathleen D Lyons, ScD
Contact
KLyons2@mghihp.edu
617-643-5372
Sheel Singh, MA
Contact
ssingh@mghihp.edu
617-724-9835‬‬‬‬‬‬‬‬‬
Kathleen D Lyons, ScD
principal investigator · MGH Institute of Health Professions

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion